US Stock MarketDetailed Quotes
ICVX Icosavax
Watchlist
10.380
-0.750-6.74% Close 11/28 16:00 ET
10.770High9.895Low314.27KVolume
10.770Open11.130Pre Close3.28MTurnover1.07%Turnover RatioLossP/E (TTM)519.94MMarket Cap16.45052wk HighLossP/E (Static)50.09MShares3.12052wk Low2.24P/B304.24MFloat Cap49.990Historical High--Dividend TTM29.31MShs Float2.280Historical Low--Div YieldTTM7.86%Amplitude10.427Avg Price1Lot Size
About Icosavax Company
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.
Company Profile
SymbolICVX
Company NameIcosavax
Listing Date07/29/2021
Issue Price15.00
Founded2017
CEOMr. Adam Simpson
MarketNASDAQ
Employees60
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1930 Boren Avenue,Suite 1000
CitySeattle
ProvinceWashington
CountryUnited States of America
Zip Code98101
Phone1-206-737-0085
Websitehttp://www.icosavax.com
Company Executives
- Name
- Position
- Salary
- Adam Simpson
- Chief Executive Officer, Director and President
- 6.91M
- Thomas Joseph Russo, C.F.A.
- Chief Financial Officer and Principal Accounting Officer
- 5.60M
- Dr. Douglas Holtzman, PhD
- Chief Scientific Officer
- 349.25K
- Dr. Niranjan Kanesa-thasan, M.D.
- Chief Medical Officer
- 2.22M
- Dr. Cassia Cearley, PhD
- Chief Business Officer
- 2.38M
- Elizabeth Bekiroglu
- General Counsel and Corporate Secretary
- 7.85M
- Mark D. Mcdade
- Chairman of the Board
- 234.02K
- Heidi Kunz
- Independent Director
- 196.52K
- Ann M. Veneman
- Independent Director
- 184.71K
- Dr. Peter Kolchinsky, PhD
- Independent Director
- 184.52K
- Dr. John W. Shiver, PhD
- Independent Director
- 710.77K
- James Wassil
- Independent Director
- 307.59K
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--